These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 28095918)

  • 1. Anti-staphylococcal activity resulting from epithelial lining fluid (ELF) concentrations of amikacin inhale administered via the pulmonary drug delivery system.
    Ghazi IM; Grupper M; Nicolau DP
    Ann Clin Microbiol Antimicrob; 2017 Jan; 16(1):2. PubMed ID: 28095918
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibacterial activity of human simulated epithelial lining fluid concentrations of amikacin inhale alone and in combination with meropenem against Acinetobacter baumannii.
    Ghazi IM; Grupper M; Nicolau DP
    Infect Dis (Lond); 2017; 49(11-12):831-839. PubMed ID: 28758820
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibacterial activity of achievable epithelial lining fluid exposures of Amikacin Inhale with or without meropenem.
    So W; Crandon JL; Hamada Y; Nicolau DP
    J Antimicrob Chemother; 2016 Feb; 71(2):428-37. PubMed ID: 26559690
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibacterial Activity of Human Simulated Epithelial Lining Fluid Concentrations of Ceftazidime-Avibactam Alone or in Combination with Amikacin Inhale (BAY41-6551) against Carbapenem-Resistant Pseudomonas aeruginosa and Klebsiella pneumoniae.
    Almarzoky Abuhussain SS; Kuti JL; Nicolau DP
    Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29914950
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro activity of human-simulated epithelial lining fluid exposures of ceftaroline, ceftriaxone, and vancomycin against methicillin-susceptible and -resistant Staphylococcus aureus.
    MacVane SH; So W; Nicolau DP; Kuti JL
    Antimicrob Agents Chemother; 2014 Dec; 58(12):7520-6. PubMed ID: 25288076
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and tolerability of amikacin administered as BAY41-6551 aerosol in mechanically ventilated patients with gram-negative pneumonia and acute renal failure.
    Luyt CE; Eldon MA; Stass H; Gribben D; Corkery K; Chastre J
    J Aerosol Med Pulm Drug Deliv; 2011 Aug; 24(4):183-90. PubMed ID: 21361783
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhaled amikacin for pneumonia treatment and dissemination prevention: an experimental model of severe monolateral Pseudomonas aeruginosa pneumonia.
    Motos A; Yang H; Li Bassi G; Yang M; Meli A; Battaglini D; Cabrera R; Bobi J; Pagliara F; Frigola G; Camprubí-Rimblas M; Fernández-Barat L; Rigol M; Ferrer-Segarra A; Kiarostami K; Martinez D; Nicolau DP; Artigas A; Pelosi P; Vila J; Torres A
    Crit Care; 2023 Feb; 27(1):60. PubMed ID: 36788582
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Humanized tissue pharmacodynamics of cefazolin against commonly isolated pathogens in skin and skin structure infections.
    Jain JG; Housman ST; Nicolau DP
    J Antimicrob Chemother; 2014 Sep; 69(9):2443-7. PubMed ID: 24827890
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    Lepak AJ; Zhao M; Marchillo K; VanHecker J; Andes DR
    Antimicrob Agents Chemother; 2020 Jan; 64(2):. PubMed ID: 31712210
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacodynamic activity of ceftobiprole compared with vancomycin versus methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA) using an in vitro model.
    Zhanel GG; Voth D; Nichol K; Karlowsky JA; Noreddin AM; Hoban DJ
    J Antimicrob Chemother; 2009 Aug; 64(2):364-9. PubMed ID: 19454524
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro synergism of magnolol and honokiol in combination with antibacterial agents against clinical isolates of methicillin-resistant Staphylococcus aureus (MRSA).
    Zuo GY; Zhang XJ; Han J; Li YQ; Wang GC
    BMC Complement Altern Med; 2015 Dec; 15():425. PubMed ID: 26627468
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Blondeau JM; Blondeau LD; Fitch SD
    J Chemother; 2024 Sep; 36(5):389-397. PubMed ID: 38339845
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacodynamic and pharmacokinetic profiling of delafloxacin in a murine lung model against community-acquired respiratory tract pathogens.
    Thabit AK; Crandon JL; Nicolau DP
    Int J Antimicrob Agents; 2016 Nov; 48(5):535-541. PubMed ID: 27742208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacodynamics of vancomycin at simulated epithelial lining fluid concentrations against methicillin-resistant Staphylococcus aureus (MRSA): implications for dosing in MRSA pneumonia.
    Harigaya Y; Bulitta JB; Forrest A; Sakoulas G; Lesse AJ; Mylotte JM; Tsuji BT
    Antimicrob Agents Chemother; 2009 Sep; 53(9):3894-901. PubMed ID: 19596879
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of human simulated exposures of ceftaroline administered at 600 milligrams every 12 hours against phenotypically diverse Staphylococcus aureus isolates.
    Keel RA; Crandon JL; Nicolau DP
    Antimicrob Agents Chemother; 2011 Sep; 55(9):4028-32. PubMed ID: 21670184
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhaled amikacin adjunctive to intravenous standard-of-care antibiotics in mechanically ventilated patients with Gram-negative pneumonia (INHALE): a double-blind, randomised, placebo-controlled, phase 3, superiority trial.
    Niederman MS; Alder J; Bassetti M; Boateng F; Cao B; Corkery K; Dhand R; Kaye KS; Lawatscheck R; McLeroth P; Nicolau DP; Wang C; Wood GC; Wunderink RG; Chastre J
    Lancet Infect Dis; 2020 Mar; 20(3):330-340. PubMed ID: 31866328
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacodynamic activity of azithromycin against macrolide-susceptible and -resistant Streptococcus pneumoniae simulating clinically achievable free serum, epithelial lining fluid and middle ear fluid concentrations.
    Zhanel GG; DeCorby M; Noreddin A; Mendoza C; Cumming A; Nichol K; Wierzbowski A; Hoban DJ
    J Antimicrob Chemother; 2003 Jul; 52(1):83-8. PubMed ID: 12775677
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacodynamic characterization of ceftobiprole in experimental pneumonia caused by phenotypically diverse Staphylococcus aureus strains.
    Laohavaleeson S; Tessier PR; Nicolau DP
    Antimicrob Agents Chemother; 2008 Jul; 52(7):2389-94. PubMed ID: 18411322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacodynamics of inhaled amikacin (BAY 41-6551) studied in an in vitro pharmacokinetic model of infection.
    Bowker KE; Noel AR; Tomaselli S; Attwood M; MacGowan AP
    J Antimicrob Chemother; 2018 May; 73(5):1305-1313. PubMed ID: 29562340
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of ceftaroline fosamil in a staphylococcal murine pneumonia model.
    Bhalodi AA; Crandon JL; Biek D; Nicolau DP
    Antimicrob Agents Chemother; 2012 Dec; 56(12):6160-5. PubMed ID: 22985880
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.